<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160276</url>
  </required_header>
  <id_info>
    <org_study_id>P081105</org_study_id>
    <nct_id>NCT01160276</nct_id>
  </id_info>
  <brief_title>Drug Interaction Between Colchicine and Calcineurin Inhibitors in Renal Graft Recipients</brief_title>
  <acronym>COLCHINCAL</acronym>
  <official_title>An Open Non Randomized Comparative Study Exploring Drug Interaction Between Colchicine and Calcineurin Inhibitors in 2 Groups (Ciclosporin Group and Tacrolimus Group) of Renal Graft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ciclosporin inhibits P-glycoprotein should increase colchicine bioavailability whereas
      tacrolimus should not influence colchicine disposition.

      This is a prospective, controlled, open labeled study performed in renal graft recipients
      comparing colchicine single dose (1mg) pharmacokinetics in 14 patients treated with
      tacrolimus and 14 patients treated with cyclosporin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Renal transplantation &gt;= one year

        -  eGFR (MDRD) &gt; 30ml/min

        -  hemoglobin &gt;= 11g/dl

        -  treatment with tacrolimus or cyclosporine

        -  no previous muscular disease

        -  no drugs interfering with P-glycoprotein or CYP3A activity or expression outcomes

        -  colchicine AUC, Cmax, T1/2

        -  ABCB1C3435T, CYP3A5 and SLCO1B1 genotypes
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve of plasma concentration of colchicine over time 0-∞</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Half-life of colchicine (T1/2).</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-3h colchicine to focus the analysis on the absorption phase (argument in favor of an interaction-dependent P-gp)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax observed colchicine.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual tacrolimus or cyclosporine concentrations</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABCB1 genotype at position 3435 (rs 1045642) or 3435 cc, 3435TT, heterozygotes could not be included in the tacrolimus group.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABCB1 Haplotypes composed of 3 SNPs: C3435T, G2677T / A and C1236T.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CYP3A5 Genotype: search for the allele * 1 (rs 776746): 3 possible genotypes CYP3A5 * 3 / * 3 - CYP3A5 * 3 / * 1 - CYP3A5 * 1 / * 1.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GFR calculated by MDRD formula.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug related (azathioprine, mycophenolic acid, diuretics, ACE inhibitors, ARAII)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Renal Replacement Therapies</condition>
  <arm_group>
    <arm_group_label>Cyclosporine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The first group is composed of 14 renal graft recipients under cyclosporine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The second group is composed of 14 renal graft recipients under tacrolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine+colchicine</intervention_name>
    <description>the 14 patients of the 1st group are under cyclosporine and One pill of colchimax 1mg will be taken by all the patients at Day 3.</description>
    <arm_group_label>Cyclosporine</arm_group_label>
    <other_name>Colchicine</other_name>
    <other_name>Colchimax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>the 14 patients of the second group are under tacrolimus and One pill of colchimax 1mg will be taken by all the patients at Day 3.</description>
    <arm_group_label>Tacrolimus</arm_group_label>
    <other_name>Colchicine</other_name>
    <other_name>Colchimax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with renal graft since at least 1 year

          -  Patients treated with ciclosporin or tacrolimus

          -  Are at least 18 years old.

          -  Glomerular filtration rate above 30 ml / min calculated using the MDRD formula

          -  Among the 14 patients receiving ciclosporin:

          -  The genotype is not a criterion for inclusion

          -  Among the 14 patients with tacrolimus treatment:

          -  7 genotype ABCB1 3435CC, 7 genotype ABCB1 3435TT

          -  Recent (1 month) residual concentration of tacrolimus between 5-10ng/ml

          -  Recent (1 month) residual concentration of ciclosporin between 100-200ng/ml

          -  For women : a negative pregnancy test (serum beta hCG)

          -  Realization of a medical examination.

          -  Informed consent and writing form.

        Exclusion Criteria:

          -  Abnormal transaminases (AST and ALT above the ULN Laboratory).

          -  Underlying Liver Disease (steatosis, cirrhosis, chronic hepatitis, the virus of
             hepatitis C or B).

          -  Previous history of muscle disease (drug related especially the statin type).

          -  Leukopenia (WBC &lt;3000/mm3).

          -  Hemoglobin &lt;11g/dl.

          -  Patient treated by erythropoetin (whatever its hemoglobin value).

          -  Abnormal CPK (greater than the ULN Laboratory).

          -  Prior intolerance to colchicine.

          -  Regular intake of the following medications associated with rhabdomyolyses:
             antipsychotics, cholesterol lowering agents (statins or fibrates), zidovudine,
             antidepressants (selective inhibitor of serotonin reuptake) and lithium.

          -  Patient (e) can not refrain from consuming grapefruit juice.

          -  Patient (e) taking a tea based on St John's wort.

          -  Taking drugs inducers of P-gp or CYP3A4 (rifabutin, rifampin, carbamazepine,
             phenytoin, phenobarbital, efavirenz, nevirapine, protease inhibitors, griseofulvin).

          -  Taking drugs inhibitors of P-gp or CYP3A4 (quinidine, macrolide antibiotics, azole
             antifungals, protease inhibitors, amiodarone, diltiazem, verapamil).

          -  Chronic diarrhea.

          -  ABCB1 Genotype 3435CT for patients in the tacrolimus group.

          -  Participation in another concurrent trial.

          -  Patient (e) exclusion period of another trial.

          -  Patient (e) having reached the maximum annual amount of compensation provided by law.

          -  No affiliation to French social security scheme or without CMU.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine Jacquet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology Department of BICETRE Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance publique - Hôpitaux de Paris : Bicêtre Hospital</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal graft</keyword>
  <keyword>colchicine</keyword>
  <keyword>drug interaction</keyword>
  <keyword>cyclosporine</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>renal transplantation</keyword>
  <keyword>renal transplant</keyword>
  <keyword>ABCB1</keyword>
  <keyword>CYP3A5</keyword>
  <keyword>SLCO1B1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

